Suhail Rasool is the Director of Neurodegenerative Diseases Research at Truebinding Inc. He focuses on developing diagnostic biomarkers and therapies for Alzheimer’s and other neurodegenerative diseases. Over the past five years, his key contributions include characterizing molecular probes for diagnosing Alzheimer's, Parkinson's, prion disease, cerebral amyloid angiopathy, and traumatic brain injury using the retina. He has also advanced a novel Alzheimer's diagnostic candidate and explored fluorescent probes for amyloid visualization. In late 2021, the FDA cleared an IND application for TB006, a lead product candidate for Alzheimer’s treatment